文献速递高血压冠心病心力衰竭与心肌病

降心率药物在高血压和/或心血管疾病中的结局:一项荟萃分析

Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis.
PubMed 文献 · Eur Heart J · 2025-01-01

平均随访2.7年,心率平均降低8.2次/分,冠心病风险降低16%、心力衰竭降低9%、心血管死亡降低14%、全因死亡降低13%,但不良事件导致的停药增加25%。降心率获益具有背景依赖性,在无心血管疾病的高血压患者中未见显著结局改善。

要点

  • 降心率治疗可降低冠心病、心力衰竭、心血管死亡及全因死亡风险,但增加不良事件停药风险。
  • 在无心血管疾病的高血压患者中,降心率未显著改善结局,而整个高血压人群卒中及死亡率增加。
  • 对于心率>70次/分的患者,将心率控制在65-70次/分可能合理。

核心结论

  • 降心率的获益具有背景依赖性,需权衡获益与风险,对于所有高于70次/分的心率阈值,目标65-70次/分似乎合理。

主要发现

  • 平均随访2.7年,心率平均降低8.2次/分(基线/达到心率:76.2/65.6次/分)。
  • 降心率使冠心病风险降低16%、心力衰竭降低9%、心血管死亡降低14%、全因死亡降低13%,但不良事件驱动的停药增加25%。
  • 在急性心肌梗死后和心力衰竭患者中观察到显著的死亡率降低。
  • 在无心血管疾病的高血压患者中未见显著结局变化,而整个高血压人群卒中及死亡率增加。
  • 阈值分析显示,除心力衰竭外,不同心率切点(从≥80次/分至近70次/分)对结局的影响无差异;除永久性停药呈递增趋势外,不同目标心率(从≥70次/分至<65次/分)对治疗结局的影响无差异。

临床怎么用

  • 对于心率>70次/分的患者,可考虑将心率控制在65-70次/分以优化结局,同时警惕不良事件导致的停药风险。
  • 在无心血管疾病的高血压患者中,降心率治疗需谨慎评估获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The benefits of heart rate (HR)-lowering drug treatment in hypertension remain controversial. The effects of HR lowering on cardiovascular (CV) outcomes, mortality, and adverse events in patients with hypertension and/or CV disease were evaluated. METHODS: PubMed, the Embase, and the Cochrane Library were searched for randomized trials comparing HR-lowering drugs with placebo or less intensive treatment. Risk ratios and 95% confidence intervals for eight outcomes were calculated (random-effects model). Subgroup analyses for a standard HR reduction were used to compare risk estimates in different HR groups or age strata (PROSPERO CRD42024540924). RESULTS: The database included 74 HR-lowering treatment trials (n = 157 764 patients). The average HR reduction over 2.7 years was 8.2 b.p.m. (baseline/attained HR: 76.2/65.6 b.p.m.). HR-lowering reduced coronary heart disease by 16%, heart failure by 9%, CV mortality by 14%, and all-cause mortality by 13% but increased adverse event-driven discontinuations by 25%. Significant mortality reductions were noted in post-acute myocardial infarction and heart failure. No significant outcome changes were observed with HR reduction in hypertension without CV disease, while the entire hypertensive population experienced increased stroke and mortality. Threshold analysis revealed that the effect on outcomes was not different across cutoffs (from ≥80 b.p.m. to almost 70 b.p.m.), except for heart failure. Treatment outcome effects were not different across progressively lower targets (from ≥70 b.p.m. to <65 b.p.m.), except for permanent discontinuations, which showed an incremental trend. CONCLUSIONS: The HR reduction benefits are context-dependent. Optimising outcomes while considering potential risks, targeting 65-70 b.p.m. for all HR thresholds above 70 b.p.m. seems reasonable.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sanidas E, Böhm M, Oikonomopoulou I, et al. Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis. Eur Heart J. 2025. PMID: 40279099. doi:10.1093/eurheartj/ehaf291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。